What Provask Treats: Main Uses and Benefits

Provask is applied within the therapeutic domains of specific, chronic cardiovascular conditions. It provides supportive relief across therapeutic domains involving systemic imbalance and symptoms that create noticeable physiological strain.

The medication is commonly used to treat persistent elevated blood pressure (hypertension), certain forms of chest pain (angina pectoris), and to provide support in patients with recently documented coronary artery disease. This use is considered relevant for managing risks associated with major future cardiovascular complications.

“This medication is primarily used to assist with the management of chronic conditions presenting with systemic or localized discomfort.”

For those experiencing chest discomfort, the medication helps manage and prevent episodes of angina, which includes chronic stable angina and vasospastic angina. This benefit generally contributes to easing the overall symptom load and assists with maintaining functional stability.

---

Quick Fact: Relief for Angina Provask is commonly used to help with symptoms related to Myocardial Ischemia, the recurring episodes of chest discomfort characteristic of inadequate circulatory support to the heart muscle. The use assists with maintaining functional stability during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Provask?

Provask (amlodipine) eligibility is determined by specific regulatory criteria defined by health authorities.

Population Status	Eligibility Rule
Allowed Populations	Adults and pediatric patients aged 6 to 17 years (for hypertension only).
Contraindicated Groups	Patients with known allergy to amlodipine or other dihydropyridine medicines. Individuals experiencing severe hypotension, cardiogenic shock, or conditions like high-grade Aortic Stenosis.

Special Considerations

Use is not established for children younger than six years old for any indication. The medicine should be used with caution in patients with hepatic impairment (impaired liver function) and in older adults, where a lower initial dose is generally advised. No specific dose adjustment is typically required for patients with renal impairment.

For pregnancy, use is generally only recommended when the potential benefits outweigh the risks, as safety has not been established. Provask is not recommended during breastfeeding, as amlodipine is known to be excreted into human milk.

Provask is a combination medication containing amlodipine (a calcium channel blocker) and atorvastatin (a statin). Because it contains two active ingredients, it is subject to the interactions of both.

Interactions with Other Medicines

Certain medicines can increase the concentration of atorvastatin in the blood, which raises the risk of serious side effects like rhabdomyolysis (severe muscle breakdown). Your physician may need to adjust the dose of Provask or monitor you closely if you take:

• Antifungals: such as itraconazole or posaconazole.
• Certain Antibiotics: such as clarithromycin or erythromycin.
• HIV/Hepatitis C Protease Inhibitors: such as ritonavir.
• Immunosuppressants: such as cyclosporine or tacrolimus.

Taking Provask with other statins (like simvastatin or lovastatin) or colchicine can also increase the risk of muscle problems. Other blood pressure medicines, such as beta-blockers or MAO inhibitors, may cause an additive blood pressure-lowering effect when combined with Provask.

---

Food and Lifestyle Interactions

• Grapefruit Juice: Consuming large amounts (more than 1.2 liters per day) of grapefruit juice can increase the blood levels of the atorvastatin component and heighten the risk of severe muscle side effects.
• Alcohol: Limit alcohol intake, as excessive amounts can increase the risk of liver damage associated with the atorvastatin component. Always inform your healthcare provider about your typical alcohol consumption.

Provask (Amlodipine) modulates the circulatory system through two primary and interconnected mechanistic domains that influence vascular tone and cardiac workload.

Selective Ca^2+ Channel Blockade and Vascular Relaxation

Provask works by acting as an inhibitor of the Voltage-dependent L-type calcium channels ( Ca v1.2) found on the membrane of arterial smooth muscle cells. This molecular blockade prevents the essential influx of extracellular calcium ions ( Ca^2+) needed to initiate muscle fiber contraction. By interrupting this crucial signaling step, the drug induces the relaxation and widening of peripheral arteries and arterioles.

Systemic Resistance Reduction and Myocardial Consumption

The widespread relaxation of arterial walls directly reduces the overall physical opposition to blood flow, known as Total Peripheral Resistance (TPR), which causes a reduction in systemic arterial pressure. This decrease in resistance also reduces the mechanical workload (afterload) on the heart, which consequently lowers myocardial oxygen consumption ( MVO2). The mechanism also causes dilation of the coronary arteries, increasing blood flow to the myocardium.

How to Use Provask: Official Administration Guidelines

Provask (amlodipine) is approved for oral administration only and is characterized by a high-level usage pattern designed for long-term maintenance therapy for chronic conditions. Administration is based on a once-daily schedule, with specific rules governing dosing, intake conditions, and patient-specific adjustments.

---

Administration Protocol

Provask can be taken with or without food, and patients are directed to take the dose at approximately the same time each day to ensure consistent drug levels in the bloodstream. The medication is primarily available as an oral tablet (2.5 mg, 5 mg, 10 mg), which should typically be swallowed whole. The 5 mg tablet is generally not manufactured to be split to achieve the 2.5 mg dose.

Standard Dosing and Adjustment

The standard initial dose for adults with hypertension or angina is 5 mg once daily, up to a maximum recommended dose of 10 mg once daily. Doses are adjusted according to therapeutic response, but changes should be made gradually, typically over a period of 7 to 14 days, to allow the body to fully reach steady-state drug levels.

Use in Specific Populations

Guidelines detail modifications for specific patient groups:

• Older Adults and Fragile Patients: A lower initial dose of 2.5 mg once daily may be used.
• Hepatic Impairment: Dosing must begin at the lower end of the range (2.5 mg or 5 mg) and be titrated slowly.
• Pediatric (Ages 6–17) Hypertension: The dose starts at 2.5 mg, with a maximum dose of 5 mg once daily.

If a dose is missed, it is generally advised to take it as soon as it's remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to prevent taking a double dose.

Research Evidence / Overview of Studies for Provask (Amlodipine)

---

Evidence for Use in Managing Elevated Blood Pressure (Hypertension)

Research exploring Provask for persistent elevated blood pressure (hypertension) involves extensive, large-scale randomized controlled trials (RCTs) and multiple meta-analyses. These long-term studies, often lasting 3 to 6 years, included both adults and older adults. Researchers examined and monitored outcomes related to changes in both systolic and diastolic blood pressure over time. They also explored the long-term impact on serious outcomes, such as the incidence of stroke and myocardial infarction.

Regulatory reviews note that trials reported measured changes in blood pressure readings, and studies comparing an amlodipine-based regimen to non-calcium channel blocker regimens monitored outcomes such as stroke and myocardial infarction in the high-risk population that was observed. Multiple trials reported measurements on blood pressure changes in adults across different follow-up periods. The evidence base is derived from multiple large-scale studies, providing context but not individual predictions about patient response.

---

Evidence for Use in Treating Chest Pain (Angina Pectoris)

Provask was evaluated in dedicated Randomized Controlled Trials (RCTs) for managing chronic stable angina and vasospastic angina. These studies included adult populations presenting with conditions characterized by fluctuating or episodic manifestations of chest pain. Research examined and monitored outcomes related to physical discomfort, such as the reported frequency of angina episodes and the amount of nitroglycerin consumption needed for relief. Studies also explored outcomes reflecting daily functioning, specifically exercise tolerance and the time until symptoms became noticeable during exertion.

In these research scenarios, studies reported measurements showing changes in the reported frequency of angina episodes and corresponding changes in the reported need for emergency nitroglycerin use. Research has explored the evidence for conditions involving periods of heightened symptoms, such as vasospastic angina. The body of evidence for angina is primarily focused on outcomes related to physical discomfort and functional capacity over the short-to-medium term.

---

What Remains Uncertain and Research Gaps

While the evidence for use in adults has been well-established, long-term effects are not fully established for all groups. Long-term effects are not fully established for the pediatric population; while studies examined short-term changes, there is an acknowledged need for more comprehensive, extended-duration data on their overall development. Findings were mixed regarding the study outcomes related to slowing plaque progression in arteries when studied in patients with coronary artery disease. The precision of findings varies across studies regarding the comparison of patterns against other classes of cardiovascular medicines. This research does not determine whether an individual will respond similarly.

Storage and Disposal Requirements

Provask (amlodipine) must be stored according to regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Amlodipine tablets must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The product must be protected from light, excess heat, and moisture and should not be frozen. Storage must be in the tightly closed, light-resistant container in which it was dispensed.

Child Safety

As required by labeling, the medication must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Provask should be disposed of using a drug take-back program whenever possible. If this is unavailable, the medicine must be prepared for household trash by mixing it with an undesirable substance, such as coffee grounds or cat litter, before placing the mixture in a sealed bag or container. This product is not on the FDA's flush list.